Delving into the Latest Updates on Biomed Industries, Inc. with Synapse

Overview

Tags

Nervous System Diseases

Respiratory Diseases

Infectious Diseases

Small molecule drug

Synthetic peptide

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	4
Infectious Diseases	3
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	7
Synthetic peptide	1
Chemical drugs	1

Top 5 Target	Count

GR(Glucocorticoid receptor)	1
SSTR(Somatostatin receptor)	1
GCGR x GIPR x GLP-1R x IGF-1R	1

A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with T2DM.

Start Date06 May 2024

Sponsor / Collaborator

Biomed Industries, Inc.

NCT04452565 / Unknown statusPhase 2/3

Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.

Start Date15 Jun 2022

Sponsor / Collaborator

NeuroActiva, Inc.

[+1]

100 Clinical Results associated with Biomed Industries, Inc.

Login to view more data

0 Patents (Medical) associated with Biomed Industries, Inc.

Login to view more data

2

Literatures (Medical) associated with Biomed Industries, Inc.

23 Nov 2021·Journal of Alzheimer's DiseaseQ3 · MEDICINE

Aduhelm: The Best Hope for Alzheimer’s Disease Patients or the Worst Decision the FDA Has Ever Made?

Q3 · MEDICINE

Author: Kurkinen, Markku ; Tran, Lloyd

Advances in Clinical and Experimental Medicine

Alzheimer’s trials: A cul-de-sac with no end in sight

Author: Kurkinen, Markku

We don’t understand Alzheimer, its origin and disease mechanisms. The absence of disease-modifying treatments for Alzheimer today is due to the amyloid hypothesis, a misguided hypothesis of Alzheimer’s disease etiology, which has dominated Alzheimer research, drug development, and clinical trials for 30 years. However, the hypothesis is not dead yet, as exemplified by the recent resurrection of clinical trials with aducanumab. Recent advances in Alzheimer research include astrocytes, synaptic function and glutamate signaling. Many studies indicate EAAT2 as a promising target in drug discovery and clinical development for novel therapies in Alzheimer’s disease, and other neurologic and psychiatric diseases.

100 Deals associated with Biomed Industries, Inc.

Login to view more data

100 Translational Medicine associated with Biomed Industries, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

7

1

Phase 3 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Traneurocin	Alzheimer Disease More	Phase 3
NA-931 ( GCGR x GIPR x GLP-1R x IGF-1R )	Obesity More	Phase 2
NA-731	Brain Injuries, Traumatic More	Phase 2
Nanomedivir	COVID-19 More	Phase 2
NA-911	Stroke More	Phase 2